ethyl N-methyl-N-ethoxycarbonylaminooxyacetate | 5767-02-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl N-methyl-N-ethoxycarbonylaminooxyacetate
• 英文别名: N-Aethoxycarbonyl-N-methyl-aminooxy-essigsaeure-aethylester；Ethyl 2-[ethoxycarbonyl(methyl)amino]oxyacetate
• CAS: 5767-02-2
• 化学式: C₈H₁₅NO₅
• 分子量: 205.211
• InChiKey: RWMSFORGNBHRCY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  65.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl N-methyl-N-ethoxycarbonylaminooxyacetate 在 盐酸 作用下， 生成 N-methylaminooxyacetic acid
  参考文献：
  名称：

  Kornowski,H. et al., Bulletin de la Societe Chimique de France, 1966, p. 683 - 686

  摘要：

  DOI：
• 作为产物：
  描述：

  ethyl N-(ethoxycarbonyl)aminooxyacetate 、 碘甲烷 在 potassium carbonate 作用下， 以 乙醇 为溶剂， 反应 3.0h， 生成 ethyl N-methyl-N-ethoxycarbonylaminooxyacetate
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of Thio-Containing Compounds with Serum HDL-Cholesterol-Elevating Properties

  摘要：

  A novel series of substituted sulfanyldihydroimidazolones (1) that modulates high-density lipoprotein cholesterol (HDL-C) has been reported to have HDL-elevating properties in several animal models. Concerns about the chemical and metabolic stability of I directed us to explore the structure-activity relationship (SAR) of a related series of substituted thiohydantoins (2). Expansion of the scope of the thiohydantoin series led to exploration of compounds in related thio-containing ring systems 3-7 and the N-cyanoguanidine derivative 8. Compounds were tested sequentially in three animal models to assess their HDL-C elevating efficacy and safety profiles. Further evaluation of selected compounds in a dose-response paradigm culminated in the identification of compound 2.39 as a candidate compound for advanced preclinical. studies.

  DOI：

  10.1021/jm030219z

文献信息

• 3-thioxo-[1,2,4]-oxadiazinan-5-one derivatives
  申请人：American Home Products Corporation

  公开号：US20020061883A1

  公开（公告）日：2002-05-23

  1 wherein R is alkyl, alkenyl, or alkynyl; R 1 and R 2 are each independently hydrogen alkyl, or aryl; and Ar is phenyl, indanyl, benzhydryl, or phenyl, substituted with one or more groups selected from the group consisting of halogen, alkyl, perfluoroalkyl, lower alkoxy, perfluoroalkylalkoxy, dialkylamino, and aroyloxy.

  其中R为烷基、烯基或炔基；R1和R2各自独立地为氢、烷基或芳基；Ar为苯基、茚基、苄基或苯基，其上取代一个或多个来自卤素、烷基、全氟烷基、低烷氧基、全氟烷氧基、二烷基胺基和芳酰氧基的基团。
• Amino thioxomethyl amino oxyacetic acid derivatives
  申请人：American Home Products Corporation

  公开号：US20020045776A1

  公开（公告）日：2002-04-18

  Antiatherosclerotic compounds are provided which have the following structure: 1 wherein R is lower alkyl; R 1 is hydroxy, amino, or lower alkoxy, R 2 and R 3 are each independently hydrogen, alkyl or aryl; Ar is phenyl, indanyl, benzhydryl, or phenyl substituted with one or more member selected from the group consisting of halogen, lower alkyl, perfluoroalkyl, lower alkoxy, perfluoroalkylalkoxy, dialkylamino, and aryloxy; or pharmaceutically acceptable salts thereof.

  提供了具有以下结构的抗动脉粥样硬化化合物：其中R是较低的烷基；R1是羟基、氨基或较低的烷氧基；R2和R3各自独立地是氢、烷基或芳基；Ar是苯基、茚基、苯甲基或苯基，其中一个或多个成员被选自卤素、较低的烷基、全氟烷基、较低的烷氧基、全氟烷氧基、二烷基氨基和芳氧基组成的群体所取代；或其药用盐。
• US6472430B2
  申请人：——

  公开号：US6472430B2

  公开（公告）日：2002-10-29
• US6562814B2
  申请人：——

  公开号：US6562814B2

  公开（公告）日：2003-05-13
• [EN] 3-THIOXO-[1,2,4]-OXADIAZINAN-5-ONE AND THEIR USE AS ANTI-ANTHEROSCLEROTIC AGENTS<br/>[FR] 3-THIOXO-[1,2,4]-OXADIAZINAN-5-ONES ET LEUR UTILISATION COMME AGENTS ANTIATHEROSCLEREUX
  申请人：AMERICAN HOME PROD

  公开号：WO2002028845A1

  公开（公告）日：2002-04-11

  This invention relates to 3/thioxo/[1,2,4]-oxadiazinan-5-one derivatives of formula: (I), wherein R is alkyl, alkenyl, or alkynyl; R1 and R2 are each independently hydrogen, alkyl, or aryl; and Ar is phenyl, indanyl, benzhydryl, or phenyl, substituted with one or more groups selected from the group consisting of halogen, alkyl, perfluoroalkyl, lower alkoxy, perfluoroalkoxy, dialkylamino, and aroyloxy; that elevate HDL cholesterol concentration, and which may be useful for the treatment of atherosclerotic conditions such as coronary heart disease.